{"id":"https://openalex.org/W4367304167","doi":"https://doi.org/10.1212/wnl.0000000000202558","title":"Use of Real-World Data to Evaluate the Importance of Antiemetic Pretreatment for Apomorphine hydrochloride [APO, Apokyn\u00ae] subcutaneous Injection Initiation and Maintenance in People with Parkinson Disease (P13-11.016)","display_name":"Use of Real-World Data to Evaluate the Importance of Antiemetic Pretreatment for Apomorphine hydrochloride [APO, Apokyn\u00ae] subcutaneous Injection Initiation and Maintenance in People with Parkinson Disease (P13-11.016)","publication_year":2023,"publication_date":"2023-04-25","ids":{"openalex":"https://openalex.org/W4367304167","doi":"https://doi.org/10.1212/wnl.0000000000202558"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.0000000000202558","doi":"https://doi.org/10.1212/wnl.0000000000202558","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000202558","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5044871280","display_name":"Cindy Happel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138615","display_name":"Supernus Pharmaceuticals (United States)","ror":"https://ror.org/03sd6kg46","country_code":"US","type":"company","lineage":["https://openalex.org/I4210138615"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cindy Happel","raw_affiliation_strings":["Medical Affairs, Supernus Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Affairs, Supernus Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210138615"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050424678","display_name":"Mindy S. Grall","orcid":"https://orcid.org/0009-0004-7881-8635","observed_orcids":["https://orcid.org/0009-0004-7881-8635"]},"institutions":[{"id":"https://openalex.org/I4210138615","display_name":"Supernus Pharmaceuticals (United States)","ror":"https://ror.org/03sd6kg46","country_code":"US","type":"company","lineage":["https://openalex.org/I4210138615"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mindy Grall","raw_affiliation_strings":["Medical Affairs, Supernus Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Affairs, Supernus Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210138615"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5057886606","display_name":"Andrea E. Formella","orcid":"https://orcid.org/0000-0003-2737-7898","observed_orcids":["https://orcid.org/0000-0003-2737-7898"]},"institutions":[{"id":"https://openalex.org/I4210138615","display_name":"Supernus Pharmaceuticals (United States)","ror":"https://ror.org/03sd6kg46","country_code":"US","type":"company","lineage":["https://openalex.org/I4210138615"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrea Formella","raw_affiliation_strings":["Medical Affairs, Supernus Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Affairs, Supernus Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210138615"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210138615"],"apc_list":null,"apc_paid":null,"fwci":0.4753,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.57675808,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"100","issue":"17_supplement_2","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9473000168800354,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9473000168800354,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11785","display_name":"Nausea and vomiting management","score":0.02319999970495701,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10919","display_name":"Deep Brain Stimulation and Movement Disorders","score":0.0038999998942017555,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.8830000162124634},{"id":"https://openalex.org/keywords/trimethobenzamide","display_name":"trimethobenzamide","score":0.9190000295639038},{"id":"https://openalex.org/keywords/drug-shortages","display_name":"drug shortages","score":0.8880000114440918},{"id":"https://openalex.org/keywords/nausea-and-vomiting","display_name":"nausea and vomiting","score":0.6980000138282776},{"id":"https://openalex.org/keywords/off-episodes","display_name":"OFF episodes","score":0.8090000152587891},{"id":"https://openalex.org/keywords/dopamine-agonists","display_name":"dopamine agonists","score":0.7450000047683716},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.6890000104904175},{"id":"https://openalex.org/keywords/drug-self-administration","display_name":"self-administration","score":0.546999990940094},{"id":"https://openalex.org/keywords/clinical-educators","display_name":"clinical instructors","score":0.5509999990463257},{"id":"https://openalex.org/keywords/real-world-data","display_name":"real-world data","score":0.7829999923706055},{"id":"https://openalex.org/keywords/treatment-tolerability","display_name":"treatment tolerability","score":0.6970000267028809},{"id":"https://openalex.org/keywords/patient-education","display_name":"patient education","score":0.34200000762939453},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.37400001287460327},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.3479999899864197}],"concepts":[{"id":"https://openalex.org/C2780884295","wikidata":"https://www.wikidata.org/wiki/Q575136","display_name":"Antiemetic","level":3,"score":0.8027681112289429},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7166078686714172},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6949449181556702},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.6265122890472412},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.574861466884613},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.5250687003135681},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.362876832485199},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.32704442739486694},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.31408053636550903},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.21990367770195007}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.0000000000202558","doi":"https://doi.org/10.1212/wnl.0000000000202558","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.0000000000202558","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4394602231","https://openalex.org/W7172282379","https://openalex.org/W4409534882","https://openalex.org/W4312054039","https://openalex.org/W4400613973","https://openalex.org/W4360840743","https://openalex.org/W4386070827","https://openalex.org/W2101789850","https://openalex.org/W4291960536","https://openalex.org/W4303987086"],"abstract_inverted_index":{"Objective:":[0],"Real-world":[1],"data":[2],"from":[3,133,194],"a":[4,67,79,147,207],"clinical":[5],"educator":[6],"(CE)":[7],"database":[8,130],"was":[9,95,131],"used":[10],"to":[11,29,72,92,112,117,135,185,200],"evaluate":[12],"whether":[13,93],"changes":[14],"in":[15,34,65,86,123,196,272,278,301,322,358,365],"antiemetic":[16,56,81,191,294],"availability":[17],"affected":[18],"Apokyn":[19,120],"treatment":[20,28,164],"maintenance.":[21],"Background:":[22],"APO":[23,48,85,144,157,188],"is":[24],"an":[25,313,333,348],"\u201con":[26],"demand\u201d":[27],"rapidly":[30],"alleviate":[31],"OFF":[32],"episodes":[33],"people":[35],"with":[36,47,58,84,223],"Parkinson":[37],"Disease":[38],"(PwP).":[39],"To":[40],"decrease":[41],"potential":[42],"for":[43,82,153,173,179,310,330,345],"nausea":[44],"and":[45,88,121,125,160,198,220,232,235,261,264,276],"vomiting":[46],"initiation":[49,124,158,170,210,249],"(a":[50,151,171],"common":[51],"dopamine":[52],"agonist":[53],"side":[54],"effect),":[55],"pretreatment":[57,94,192],"trimethobenzamide":[59],"(Tigan)":[60],"has":[61,299,306,320,326,341,356,363],"been":[62],"recommended.":[63],"However":[64],"2021,":[66],"widespread":[68],"Tigan":[69,148,154,186,208,269,274],"shortage":[70,187],"(due":[71],"cessation":[73],"of":[74,100,140,169,204,248,315,335,350],"manufacturing),":[75],"left":[76],"clinicians":[77],"without":[78,190,293],"suitable":[80],"use":[83,270],"PwP":[87,286],"questions":[89],"arose":[90],"as":[91,312,332,347],"needed.":[96],"Design/Methods:":[97],"The":[98,128],"Circle":[99],"Care":[101],"(CoC)":[102],"program":[103],"(sponsored":[104],"by":[105,202,268],"Supernus":[106,302,316,351,366],"Pharmaceuticals)":[107],"provides":[108],"Clinical":[109],"Educators":[110],"(CEs)":[111],"teach":[113],"consenting":[114],"patients":[115,141],"how":[116],"correctly":[118],"self-administer":[119],"aid":[122],"maintenance":[126],"needs.":[127],"CoC":[129],"analyzed":[132],"2019\u20132021":[134],"determine":[136],"1)":[137],"the":[138,217,255],"percentage":[139],"first":[142],"initiating":[143,238],"who":[145],"received":[146,307,327,342],"reminder":[149],"call":[150],"proxy":[152,172],"use),":[155],"2)":[156],"dose":[159],"3)":[161],"all":[162],"cause":[163,243],"discontinuation":[165,244],"within":[166,245],"90":[167,246],"days":[168,247],"tolerability).":[174],"Results:":[175],"Data":[176],"were":[177],"available":[178],"1910":[180],"unique":[181],"patient":[182],"starts.":[183],"Due":[184],"initiations":[189],"rose":[193],"30%":[195],"2019":[197],"2020":[199],">80%":[201],"end":[203],"2021.":[205],"Despite":[206],"shortage,":[209],"doses":[211],"did":[212,265],"not":[213,266],"change":[214],"substantially":[215],"across":[216,254],"2019,":[218],"2020,":[219],"2021":[221],"evaluation":[222,257],"35.5%.":[224],"34%.":[225],"39.5%,":[226],"respectively,":[227,237],"starting":[228],"at":[229,239],"1.0":[230],"mg":[231],"59%,":[233],"61%,":[234],"57%,":[236],"2.0":[240],"mg.":[241],"All":[242],"also":[250],"remained":[251],"largely":[252],"constant":[253],"3-year":[256],"period":[258],"(26%,":[259],"23%":[260],"23%,":[262],"respectively)":[263],"differ":[267],"[23%":[271],"both":[273],"users":[275],"nonusers":[277],"2021].":[279],"Conclusions:":[280],"Overall,":[281],"our":[282],"analysis":[283],"demonstrates":[284],"that":[285],"can":[287],"successfully":[288],"initiate":[289],"apomorphine":[290],"SC":[291],"injection":[292],"prophylaxis.":[295],"Disclosure:":[296],"Cindy":[297],"Happel":[298],"stock":[300,321,357,364],"Pharmaceutical.":[303],"Ms.":[304,318],"Grall":[305,319],"personal":[308,328,343],"compensation":[309,329,344],"serving":[311,331,346],"employee":[314,334,349],"Pharmaceuticals.":[317,360],"Supernus.":[323],"Dr.":[324,339,354,361],"Formella":[325,340,355,362],"Adamas":[336,359],"Pharmaceuticals,":[337,352,367],"Inc.":[338,353],"Inc..":[368]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-29T00:00:00"}